At its meeting on 08 August 2022 the Transparency Council adopted Position No. 72/2022 on the legitimacy of granting consent for reimbursement of the drug Fycompa (perampanel) for the indications: drug-resistant epilepsy, drug-resistant epilepsy with focal seizures.